Kei Kishimoto

Company: Selecta Biosciences Inc.

Job title: Chief Scientific Officer

Seminars:

Translating Antigen-Specific Immune Tolerance Approaches to Mitigate Immunogenicity of Biologic Therapies 2:35 pm

Dive into harnessing antigen-specific immune tolerance strategies and expertise to inhibit unwanted immune responses against protein and enzyme therapies, AAV gene therapies, and more. Capitalize on your antigen-specific autoimmune tolerance approaches and capture this opportunity at your fingertips. Understanding which cell populations become tolerized in drug-specific tolerance approaches Discussing pros and cons of applying antigen-specific…Read more

day: Pre-Conference Workshop Day